http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Signal transduction of 4-1BB for CD8+ T cell survival
Pakr, SJ,Choi, BK,Kim, HH,Nam, KO,Kwon, BS,Lee, HW 이화여자대학교 세포신호전달연구센터 2002 고사리 세포신호전달 심포지움 Vol. No.4
Engagement of two signals, T cell receptor(TCR) and co-stimulatory molecule, are necessary for proper activation of T cells. Co-stimulatory signals in T cell are provided by the corresponding ligands on antigen presenting cells(APC). TCR signal alone leads to T cell anergy. 4-1BB, one of co-stimulatory molecules, is a member of TNF receptor superfamily and expressed on T cells upon TCR ligation. It is well known that 4-1BB is co-stimulatory molecule enhancing proliferation and inhibiting activation-induced cell death(AICD) of T cells. Moreover, 4-1BB has been appreciated as a critical molecule for enhancing immune rejection in allograft transplantation, eradication of tumor, integrin-mediated T cell adhesion, and T cell-mediated cytolysis. It is reported that 4-1BB-mediated co-stimulation is involved in responses of CD4+ and CD8+ T cell To elucidate molecular mechanisms by which 4-1BB enhances proliferation and survival of T cells, we purified CD8+ T cells and investigated the effect of 4-1BB on T cell activation. 4-1BB stimulation increased proliferation and survival of CD8+ T cells. 4-1BB-mediated proliferation was inhibited by pharmacological blockers for NF B and PI3-kinase(PDTC and LY294002, respectively). 4-1BB stimulation up-regulated expression of anti-apoptotic gene, Bcl-X_(L) mRNA and protein, and the effect of 4-1BB on Bcl-X_(L) was blocked by NF B inhibitor, but not by PI3-kinase inhibitor. Beads conjugated with anti-CD3 plus anti-4-1BB antibody induced raft formation at the site where T cells contacts to beads, suggesting 4-1BB ligation recruits signaling molecules such as PKC and IKK to initiate T cell signaling. 4-1BB induced NF B activation as shown by I B degradation, whereas it did not increase phosphorylation of Akt, downstream kinase activated by PI-3 kinase. These data suggest that 4-1BB ligation activates signaling events in raft which results in CD8+ T cell activation. 4-1BB-evoked NF B activation may be responsible for up-regulation of Bcl-X_(L) expression, which could be one of mechanisms by which 4-1BB enhances survival and proliferation of T cells.
난소 내배엽동 종양에서 BEP 복합화학요법에 의한 완전관해 1 예
이승준(SJ Lee),이찬근(CG Lee),황성연(SY Hwang),권상철(SC Kwon),김창홍(CH Kim),김홍곤(HG Kim),윤기중(KJ Yoon) 대한산부인과학회 1997 Obstetrics & Gynecology Science Vol.40 No.11
Endodermal sinus tumors(EST) have also been referred to as yolk sac tumors because they are derived from the primitive yolk sac. These lesions are the third most frequent malignant germ-cell tumors of the ovary. Recent advances in treating the endodermal sinus tumor of the ovary with the combination chemotherapy result in improvement of the prognosis. We had experienced a case of the endodermal sinus tumor of 15 year old woman. We report this case with a brief review of literatures.
자궁경부암에서 cis-Platin을 포함한 복합항암요법에 의한 오심 및 구토의 조절에 있어 Ondansetron-Dexamethasone의 효과에 대한 비교분석
김승조,송승규,권용일,김미란,이유미,한상균,남궁성은 대한부인종양 콜포스코피학회 1993 Journal of Gynecologic Oncology Vol.4 No.2
Chemotherapy induced nausea and vomitting remain important concerns for patients. In recent years, many antiemetics based on diphenhydramine, dexamethasone, metoclopramide or lorazepam have eiinically demonstrable antiemetie effects. Cis-Platin, which is one of the most effective chemotherapeutic agents, produces severe emesis after its administration and delayed emesis also. Metoclopramide, which is a potent dopamine receptor antagonist, have been shown to be safe and effective single agent for the control of nausea and vomitting. But the antiemetic effects of metoclopramide was thought to be mediated by dopamine receptor blockade and so produced adverse events like as extrapyramidal reactions. Recently, Ondansetron is a highly selective 5-HT, (5-Hydroxytryptamine,) receptor antagonist that dose not have any activity at dopamine receptors. It has been shown to be an effective antiemetic activity especially when combined with dexamethasoe and also be safe and less side effects. All patients suffering from a diaease with cervical cancer were receiving cis-Platin (80 to 120 mg/ m) containing combination chemotherapy. OD( Ondan,setron (Hmg)-Dexamethasone (20mg) $gt;was given to 30 patiente. Their mean ages were 43 and 47 years old, respectively. In the OD group, Ondansetron 8mg and Dexamethasone 20mg were given by intravein 30 minutes prior to chemotherapy and administered intravenously by 8 hour intervals after chemotherapy on day 1 on days 2~3, the patients reveived Ondansetron at a dose of 8mg tid Fro the 3 days following, Ondansetron was administered as an oral dosage of 8 mg every 8 hours. In the MD group, Metoclopradmide 30 mg in normal saline 100ml and Dexamethasone 20mg were of given by intravein 30 minutes prior to cis-Platin administration for 30 minutes and administered intravenously by 8 hour intervals on days 1~3. For the 3 days following, the drugs were administered as an oral dosage of 30mg every 8 hours. In the MDL group, Metoclopramide 2mg/kg in normal saline 100ml, Dexamethasone 20mg and Lorazepam 1mg were fiven by intravein 30 minutes prior to chemotherapy and administered intravenously by 8 hour intervals on day 1. On days 2~3, the patients received Metoclopramide and Dexamethasone at a dosage of 2mg/kg and 20mg tid. For the 3 day following, Metoclopramide was administered by oral dosage of 100mg every 8 hours. In the OD group, MD group and MDL gorup, mausea was controlled in 100% of the patients(none:48.4%, mild $quot; 51.6%), 55% (5%, 50%(, 46%(13%, 33%) and vomitting was controlled in 100% of patients (complete: 87.1%, major: 12.9%), 60%(25%, 35%), 83%(43%, 40%) on day 1. On days 2 to 3, nausea was controlled in 71% of the patients(none: 12.9%, mild: 58.1%), 57.5(2.5%, 55%), 66.6%(13.3%, 53.3%) and vomitting was controlled in 80.7%(complete: 48.4%, major:32.3%), 67.5%(7.5%, 60%), 80%(23.3%, 56.7%). On days 4 to 6, mausea was controlled in 77.5% (none: 45.2%, mild: 32.3%), 77.5%(2.5%, 75%), 93.3%(33.3%, 60%), and vomitting was controlled in 87.1%(complete: 67.7%, major: 19.4%), 77.5%(20%, 57.5%), 96.7%(56.7%, 40%). The side effects of the OD group were mild with dystonic reaction(4 patients), headache(5 patients), constipation(5 patients), xerostomia(7 patients), nonspecific abdominal pain(6 patients) and cutaneous flushing(4 patients). In the MD group, expyramidal, side reaactions were seen with exrostomia(25 patinets), cutaneous flushing(26 patients), headache(10 patients), acute dystonic reaction(9 patients), restlessness(8 patients) and abdominal pain(8 patients), In the MDL group, the side effects were mild with sedation(6 patients), restlessness(1 patient) and no expyramidal reaction was seen, There is no patients who had treatment failure in 101 patients. the results showed that OD group was more effective than MD or MDL groups in a controlled envrionment of acute emesis induced by cis-Platin based combination chemotherapy. But in delayed emesis, the MDL group was the most effective regimen among the three groups. Lorazepam was an effective regimen in controlling the expyramidal side reactions
Younghoon Kwon,Jeongok Logan,Snigdha Pusalavidyasagar,Takatoshi Kasai,Crystal SJ Cheong,Chi-Hang Lee 대한수면학회 2019 sleep medicine research Vol.10 No.2
Scientific investigations in the past few decades have supported the important role of sleep in various domains of health. Sleep apnea is a highly prevalent yet underdiagnosed sleep disorder representing a valid cardiovascular risk factor, particularly for hypertension. While several studies have demonstrated the benefits of sleep apnea treatment on subclinical cardiovascular measures, there is a paucity of studies proving reduction of cardiovascular events and mortality. Sufficient and high-quality sleep is also important in the maintenance of cardiovascular health. Future investigations should focus on improving identification of patients at greatest risk of adverse cardiovascular sequelae of sleep apnea and testing the therapeutic benefit of sleep apnea treatment in this vulnerable group.
Mayer-Rokitansky-Kuster-Hauser 증후군 1 례
권오일(OI Kwon),최영철(YC Choe),이진건(JK Lee),조석재(SJ Cho) 대한산부인과학회 1987 Obstetrics & Gynecology Science Vol.30 No.10
저자들은 본 병원 산부인과에서 선천적 질결손증 1례를 경험 치료하였기에 문헌적 고찰과 함께 보고하는 바이다. The principal clinical features of the Mayer-Rokitansky_kuster-Hauser Syndrome are summarized as : normal female secondary sex characteristics, normal external genitalia, congenital absenece of vagina, rudimentary or bipartite uterus, normal ovarian function and normal ovulation, 46, XX, karyotype, frequent association of renal, skeletal and other congenital anomalies. A clinicopathologic study and treatment of a case of Mayer-Rokitansky-Kuster-Hauser Syndrome are carried out by authors and report with review of the literautres.